Congruently, transcriptomic data from human MASLD/MASH patients revealed reduced hepatic MARCHF6 expression alongside an increase in that of the lipogenic genes SREBF1, FASN, and SCD1. This evidence concerns the gene MARCHF6 and metabolic dysfunction-associated steatohepatitis.